Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only



| Attribute | ||
|---|---|---|
Research Summary | VIP stands for Vasoactive Intestinal Peptide. It acts like a massive relaxer for your blood vessels and lungs, opening them up to increase blood flow, lower blood pressure, and heal toxic damage from mold. | KPV is the ultimate inflammation cooler. When your immune system is freaking out and causing red, swollen, angry issues (like in the gut or on the skin), KPV acts like a fire extinguisher to instantly calm it down. |
Studied For | ARDS / acute respiratory failure researchPulmonary hypertensionSarcoidosis treatment researchErectile dysfunction (intracavernosal)COVID-19 respiratory complication researchGI motility modulationIntestinal inflammation / IBDNeurotransmission modulationVasodilation / blood pressureImmune modulationLung protectionAsthma researchPancreatic secretionCircadian rhythm modulationAnti-inflammatory cytokine modulationNeuroprotectiongut healthmold toxicityCIRSanti-inflammatorybronchodilationpulmonary hypertensionerectile dysfunctionimmune tolerance | GI inflammation / IBD researchUlcerative colitis modelsCrohn's disease modelsSkin inflammationWound healingImmune modulationNF-kB pathway inhibitionAnti-inflammatory cytokine reductionMucosal barrier integrityGut health restorationPsoriasis researchEczema researchColitis modelsMelanocortin receptor anti-inflammatorySystemic inflammation reductionOral peptide delivery researchanti-inflammatorygut healingCandidaIBDpsoriasismast cell stabilizationskin healingulcerative colitis |
Research Areas | ImmuneGut Health & GI RepairSexual Health & LibidoCognitive | Gut Health & GI RepairImmuneHealing & RecoveryPain & InflammationSkin & Hair |
Best Stacked With | ll-37thymosin-alpha-1bac-water | bpc-157ll-37thymosin-alpha-1lipo-cbac-water |
Overview | ||
Category | Immunity & Wellness | Healing & Recovery |
Compound Class | 28-amino acid neuropeptide and hormone; member of secretin/glucagon superfamily | Tripeptide C-terminal fragment of alpha-MSH (melanocyte-stimulating hormone) |
Molecular Target | VPAC1 and VPAC2 receptors (VIP/PACAP receptors); cAMP/PKA signaling; vasodilation, bronchodilation, immune modulation, GI motility | MC1R / melanocortin receptors; NF-kB inhibition; reduces TNF-alpha, IL-1beta, IL-6 production; mucosal protection |
Aliases / AKA | Vasoactive Intestinal PeptideAviptadilRLF-100VIP peptideVPAC agonistVasoactive intestinal polypeptide | Lys-Pro-ValAlpha-MSH tripeptide coreMSH fragmentKPV peptideAlpha-melanocyte-stimulating hormone C-terminal tripeptideAnti-inflammatory tripeptide |
Parent Compound | Endogenous neuropeptide | alpha-MSH C-terminal fragment |
Molecular Weight | 3325.8 Da | 342.43 Da |
Amino Acid Sequence | HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2 | Lys-Pro-Val |
CAS Number | 40077-57-4 | 67727-97-3 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 46,941 Extensive | 206 Good |
Clinical Trials | 3030 Active | Not Listed |
Regulatory Status | FDA orphan designations but not approved; investigational. | Not FDA-approved; research chemical. |
Evidence & Regulatory | ||
Half-Life | ~1-2 minutes | ~1.5 hours |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | A large randomized COVID-19 trial of IV aviptadil did not significantly improve outcomes. VIP with phentolamine is approved for erectile dysfunction in some countries. | Cell and mouse colitis studies report reduced inflammation and mucosal healing, often using targeted nanoparticle delivery. Human efficacy is not established. |
Side Effects Noted | SAFETY FLAG: infusion hypotension, diarrhea, and facial flushing; high-dose VIP can cause severe secretory diarrhea with acid-base disturbance. | Preclinical tolerability is good with low toxicity; no meaningful human adverse-event data. |
Warnings | Hypotension can be clinically important and warrants monitoring; efficacy in respiratory disease is unproven. Investigational. | No approved human indication. Research use only. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | sterile water; slow controlled IV infusion | sterile or bacteriostatic water |
Storage Temp | cold, dark | cold, dry |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Chemically labile; adsorbs to surfaces. | Small, relatively stable tripeptide. |
Reconstituted Shelf Life | 7 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Single BPC-157 versus the combined BPC-157 and TB-500 blend in recovery research.
Ipamorelin alone versus the CJC-1295 and ipamorelin blend on the growth-hormone axis.
A synthetic ACTH-fragment nootropic versus a neurotrophic peptide preparation in cognitive research.
Two sleep-research compounds with distinct mechanisms.
A copper tripeptide versus an acetyl hexapeptide in cosmetic and skin research.
A senolytic peptide versus a telomerase-pathway peptide in longevity research.
Two metabolic research compounds targeting the AMPK and NNMT pathways.
A GHRH analog versus an HGH fragment in fat-metabolism research.
Two AMPK-associated mitochondrial and metabolic research compounds.
Two peptides studied for tissue protection and repair.
Two peptides studied for immune and inflammatory modulation.
Two peptide bioregulators studied in longevity and neuro research.
A glucagon/GLP-1 dual agonist versus a GIP/GLP-1 dual agonist in metabolic research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.